Takeaway

• Salvage radiotherapy plus 6-month enzalutamide delays PSA progression in patients with PSA-recurrent high-risk prostate cancer after radical prostatectomy.

Why this matters

• Clinicians should discuss this approach with patients.

Study design

• A randomized, double-blind, phase 2, placebo-controlled, multicentre SALV-ENZA study of 86 men with biochemically recurrent prostate cancer who, after ...